<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25184924</article-id>
      <article-id pub-id-type="pmc">4155963</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20142989</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Atypical lesions in relapsed leprosy<xref ref-type="other" rid="fn01">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Raiol</surname>
            <given-names>Theisla Kely Azevedo</given-names>
          </name>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Volpato</surname>
            <given-names>Solange Emanuelle</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guimar&#xE3;es</surname>
            <given-names>Patr&#xED;cia de Barros</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lopes</surname>
            <given-names>Maria Luciana Andrade de Almeida</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takano</surname>
            <given-names>Daniela Mayumi</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Santana</surname>
            <given-names>Jaci Maria</given-names>
          </name>
        </contrib>
        <aff> Hospital Ot&#xE1;vio de Freitas (HOF) - Recife (PE), Brazil.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01"><italic>MAILING ADDRESS</italic>: Theisla Kely Azevedo Raiol, Rua
Apr&#xED;gio Guimar&#xE3;es, s/n, Tejipi&#xF3;, 50920640 - Recife - PE. Brazil
E-mail: <email>tkraiol@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Sep-Oct</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2014</year>
      </pub-date>
      <volume>89</volume>
      <issue>5</issue>
      <fpage>808</fpage>
      <lpage>811</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>01</day>
          <month>10</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2014 by Anais Brasileiros de
Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract>
        <p>Relapsed cases of leprosy are not common in patients treated regularly with the
recommended polychemotherapeutical schemes. Relapses must be readily identified and
distinguished from reactions. This article reports a clinical case of relapse in
leprosy, with atypical and exuberant skin changes in patient treated for eleven years
with a paucibacillary scheme.</p>
      </abstract>
      <kwd-group>
        <kwd>Case reports</kwd>
        <kwd>Leprosy, multibacillary</kwd>
        <kwd>Recurrence</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Among the strategies for control of Hansen's disease, an early diagnosis of cases and
their adequate treatment with recommended polychemotherapy (PCT) regimens are paramount
as recommended by World Health Organization (WHO).<sup><xref rid="r01" ref-type="bibr">1</xref></sup> Leprosy relapse cases are rare in patients treated regularly with
the recommended polychemotherapeutical schemes. Usually relapses occur in a period
greater than five years after the cure.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> Differential diagnosis between reaction and relapse must be based on
the association of clinical and laboratory exams.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup> This article describes a
clinical case of relapse, with atypical and exuberant cutaneous presentations.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 49-year-old female patient, originally from Gravat&#xE1;-PE, complained about
burning pain in feet, forearms and hands, with onset three years ago. She referred a
previous treatment for Hansen's disease 11 years ago, during six months. In the last
three years, she has used several drugs for the treatment of hansenic reaction.
According to a notification sheet, the patient had been classified under the tuberculoid
clinical form, presenting negative bacilloscopy and discharged after being considered
cured, at the end of six months of treatment (in 2002).</p>
      <p>At the current physical examination, erythematous, infiltrative and fibrotic lesions,
which followed a linear pattern on forearms, hands and feet, drew attention (<xref ref-type="fig" rid="f01">Figure 1</xref>, <xref ref-type="fig" rid="f02">2</xref> and
<xref ref-type="fig" rid="f03">3</xref>). She also presented madarosis on the full
extension of her eyebrows, distal nail dystrophy in hands and feet, and foveolar lesion
in the cervical region. Bacilloscopy was then requested, with the following result: IB:
5.75; IM: Whole Bacilli: 60; Several clumps. A histopathological exam of the
erythemato-fibrotic lesions was also requested, which evidenced a lymphohistiocytic,
periadnexal, perineural and perivascular inflammatory infiltrate, vacuolated macrophages
containing clumps, besides the presence of bacilli in Ziehl-Neelsen staining (<xref ref-type="fig" rid="f04">Figure 4</xref>). Based on the clinical history and
complementary exams, multibacillary polychemotherapy was started and the prednisone dose
was increased to 40mg/day (patient was taking 20mg/day). After one month, she already
showed great improvement of lesions on the upper limbs and of pain symptoms in hands and
feet (<xref ref-type="fig" rid="f05">Figure 5</xref>). However, the clinical improvement
of feet lesions was not as pronounced as in the upper limbs (<xref ref-type="fig" rid="f06">Figure 6</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Infiltrative linear lesions on forearms and hands. Atypical presentation pattern
in dimorphous- virchowian Hansen's disease</p>
        </caption>
        <graphic xlink:href="abd-89-05-0808-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Infiltrated lesions of atypical pattern in Hansen's disease</p>
        </caption>
        <graphic xlink:href="abd-89-05-0808-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Infiltrated lesions of atypical pattern in Hansen's disease</p>
        </caption>
        <graphic xlink:href="abd-89-05-0808-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Histopathological aspect of erythematous-infiltrate lesion, evidencing a
perineural and perivascular lymphohistiocytic inflammatory infiltrate</p>
        </caption>
        <graphic xlink:href="abd-89-05-0808-g04"/>
      </fig>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Clinical improvement of infiltrative lesions, after introduction of multibacillary
polychemotherapy</p>
        </caption>
        <graphic xlink:href="abd-89-05-0808-g05"/>
      </fig>
      <fig id="f06" orientation="portrait" position="float">
        <label>FIGURE 6</label>
        <caption>
          <p>Aspect of linear and erythematousfibrotic lesions, before the treatment. Even 30
days after the introduction of polychemotherapy, there was no remarkable
improvement of feet lesions, as occurred with forearms</p>
        </caption>
        <graphic xlink:href="abd-89-05-0808-g06"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>In leprosy, relapse should be taken into account when, after completion of adequate
treatment and discharge after the patient is considered cured, signs and symptoms of
disease activity reappear.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup> The patient had been initially classified
(11 years ago) under the tuberculoid clinical form, being treated and receiving a clean
bill of health. Afterwards it progressed with new skin lesions.</p>
      <p>Patients that present worsening of lesions after completion of treatment must be
directed to referral services for evaluation.<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>Sometimes the distinction between relapse and reaction is difficult, and it is based
mainly on clinical aspects: cutaneous lesions related to reactions usually start
earlier, during or even up to the first year after the PCT; on the other hand the
lesions that suggest relapse happen later, appearing even many years after treatment (on
average, after a period of 5 years).<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup> As opposed to lesions arising from
relapse, response to corticoids is remarkable in reactional cases.<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>According to the Ministry of Health, the criteria for diagnosing relapse for
paucibacillary (PB) cases are: the patient who, after receiving a clean bill of health,
presents pain in nerve pathways, with new lesions and/or exacerbation of previous
lesions which do not respond to treatment with corticosteroids, for at least 90 (ninety)
days; and patients with late reactional outbreaks, usually five years after being
considered healed.<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>For multibacillary cases (MB): the patient who, after receiving a clean bill of health,
presents cutaneous lesions and/or exacerbation of old lesions, new neurological changes
which do not respond to treatment with thalidomide and/or corticosteroid in recommended
doses and timeframes, positive bacilloscopy and compatible clinical picture with
patients never treated before; patients with late reactional outbreaks, usually five
years after being considered cured.</p>
      <p>In a study carried out by Brito and colleagues in 2005, in an endemic Hansen's disease
region, the clinical criterion was the most used to decide for a new relapse treatment,
followed by bacilloscopy.<sup><xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>The relapses of Hansen's disease may occur due to various factors, such as:
immunosuppression, persistence of bacillum, resistance to drugs, inadequate or irregular
therapeutics, or wrong initial classification.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup></p>
      <p>Relapses associated with drug resistance have been reported since the early 1960's,
chiefly related to long-term use of dapsone.<sup><xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup> Reports of resistance to
rifampicin (RIF) are less common, although not less important, since RIF is the main
drug of the PCT scheme, with a high bactericide effect.<sup><xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>Diniz and Col. Evidenced, in a retrospective cohort study (2009), that the magnitude of
hansenosis relapse is low, and more frequent between the dimorphous and virchowian
forms.<sup><xref rid="r07" ref-type="bibr">7</xref></sup></p>
      <p>The patient was classified under the current clinical form, as dimorphous-virchowian,
due to the presence of foveolar lesion (characteristic of the dimorphous form) and
diffuse and infiltrative lesions with positive bacilloscopy (characteristic of the
virchowian form).<sup><xref rid="r08" ref-type="bibr">8</xref></sup> She was also
diagnosed as carrier of type 1 hansenic reaction, with neuritis in upper and lower limbs
(hands and feet).</p>
      <p>It was considered a relapse due to the late onset of new lesions and no response to
anti-reactional drugs. When a new treatment was established, with a multibacillary
scheme, there was clinical improvement of lesions, and with the increased prednisone
dose there was improvement of neuritic pain. Probably the patient was classified in an
inadequate way eleven years ago (in the 1<sup>st</sup> treatment) and treated with an
insufficient scheme for the complete eradication of the bacilli. This way, there was
persistence of viable bacilli, which slowly multiplied for years, leading to the
development of exuberant clinical lesions. There was no evidence of further exposure
with nontreated communicants.</p>
      <p>When a paucibacillary patient relapses as a multibacillary one, it is very probable that
an error in classification occurred during the initial treatment.<sup><xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>For Ximenes <italic>et al</italic> (2007) and Shetty <italic>et al</italic> (2005),
patients that presented reactional episodes have greater probability of being treated as
having a relapse.<sup><xref rid="r09" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>In spite of the attested efficacy of PCT/WHO schemes, surveillance of drug resistance
must be carried out. To that end, the referral units must forward sample material of
multibacillary cases with confirmed relapse to the national referral centers which
perform this surveillance.<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
      <fn fn-type="other">
        <p>How to cite this article: Raiol TKA, Volpato SE, Guimar&#xE3;es PB, Lopes MLAA,
Takano DM, Santana JM. Atypical lesions relapsed leprosy. An Bras Dermatol.
2014;89(5):808-11.</p>
      </fn>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p>Work performed at Hospital Ot&#xE1;vio de Freitas - Recife (PE), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="web">
          <person-group person-group-type="author">
            <collab>Portal.saude.gov.br</collab>
            <collab>Brasil</collab>
            <collab>Minist&#xE9;rio da Sa&#xFA;de</collab>
            <collab>Secretaria de Vigil&#xE2;ncia em Sa&#xFA;de</collab>
          </person-group>
          <comment>[Internet]</comment>
          <source xml:lang="pt">Portaria n&#xBA; 3.125, de 7 de Outubro de 2010. Aprova as
Diretrizes para Vigil&#xE2;ncia, Aten&#xE7;&#xE3;o e Controle da
hansen&#xED;ase</source>
          <date-in-citation content-type="access-date">acesso 10 Mar 2013</date-in-citation>
          <comment>Dispon&#xED;vel em: <ext-link ext-link-type="uri" xlink:href="http://portal.saude.gov.br/portal/arquivos/pdf/portaria_n_3125_hanseniase_2010.pdf">http://portal.saude.gov.br/portal/arquivos/pdf/portaria_n_3125_hanseniase_2010.pdf</ext-link></comment>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Teixeira</surname>
              <given-names>LO</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Akamatsu</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Barreto</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>CT</given-names>
            </name>
          </person-group>
          <article-title>Neural relapse in multibacillary leprosy 6 years after end of
treatment</article-title>
          <source>An Bras Dermatol</source>
          <year>2012</year>
          <volume>87</volume>
          <fpage>310</fpage>
          <lpage>313</lpage>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brito</surname>
              <given-names>MFM</given-names>
            </name>
            <name>
              <surname>Ximenes</surname>
              <given-names>RAA</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>MEN</given-names>
            </name>
          </person-group>
          <article-title>Retreatment of leprosy relapse</article-title>
          <source>An Bras Dermatol</source>
          <year>2005</year>
          <volume>80</volume>
          <fpage>255</fpage>
          <lpage>260</lpage>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barreto</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Goya</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Miranda</surname>
              <given-names>RMC</given-names>
            </name>
          </person-group>
          <article-title xml:lang="pt">Hansen&#xED;ase dimorfa reativada: recidiva ou
tratamento insuficiente em paciente imunologicamente
suscet&#xED;vel</article-title>
          <source>Hansen Int</source>
          <year>2006</year>
          <volume>31</volume>
          <fpage>35</fpage>
          <lpage>38</lpage>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Instituto Lauro de Souza Lima</collab>
            <collab>Coordenadoria de Controle de Doen&#xE7;as</collab>
            <collab>Secretaria de Estado da Sa&#xFA;de</collab>
          </person-group>
          <article-title xml:lang="pt">Recidiva e resist&#xEA;ncia em
hansen&#xED;ase</article-title>
          <source>Rev Sa&#xFA;de P&#xFA;blica</source>
          <year>2011</year>
          <volume>45</volume>
          <fpage>631</fpage>
          <lpage>633</lpage>
          <pub-id pub-id-type="pmid">21552762</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>MLW</given-names>
            </name>
          </person-group>
          <article-title xml:lang="pt">A cura da hansen&#xED;ase x Magnitude das
recidivas</article-title>
          <source>An Bras Drematol</source>
          <year>1997</year>
          <volume>72</volume>
          <fpage>63</fpage>
          <lpage>69</lpage>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diniz</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Puppin</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>de Oliveira</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <article-title>Retrospective study on leprosy relapse in the State of Esp&#xED;rito
Santo</article-title>
          <source>Rev Soc Bras Med Trop</source>
          <year>2009</year>
          <volume>42</volume>
          <fpage>420</fpage>
          <lpage>424</lpage>
          <pub-id pub-id-type="pmid">19802479</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Opromolla</surname>
              <given-names>DVA</given-names>
            </name>
          </person-group>
          <chapter-title xml:lang="pt">Manifesta&#xE7;&#xF5;es cl&#xED;nicas e
rea&#xE7;&#xF5;es</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Opromolla</surname>
              <given-names>DVA</given-names>
            </name>
          </person-group>
          <source xml:lang="pt">No&#xE7;&#xF5;es de hansenologia</source>
          <publisher-loc>Bauru</publisher-loc>
          <publisher-name>Hospital Lauro de Souza Lima</publisher-name>
          <fpage>51</fpage>
          <lpage>57</lpage>
          <year>2000</year>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ximenes</surname>
              <given-names>RAA</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>MEN</given-names>
            </name>
            <name>
              <surname>Brito</surname>
              <given-names>MFM</given-names>
            </name>
          </person-group>
          <article-title>Retreatment in Leprosy: a case-control study</article-title>
          <source>Rev Saude Publica</source>
          <year>2007</year>
          <volume>41</volume>
          <fpage>632</fpage>
          <lpage>637</lpage>
          <pub-id pub-id-type="pmid">17589762</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shetty</surname>
              <given-names>VP</given-names>
            </name>
            <name>
              <surname>Wakade</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Ghate</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Pai</surname>
              <given-names>VV</given-names>
            </name>
            <name>
              <surname>Ganapati</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Antia</surname>
              <given-names>NH</given-names>
            </name>
          </person-group>
          <article-title>Clinical, histopathological and bacteriological study of 52 referral
MB cases relapsing after MDT</article-title>
          <source>Lepr Rev</source>
          <year>2005</year>
          <volume>76</volume>
          <fpage>241</fpage>
          <lpage>252</lpage>
          <pub-id pub-id-type="pmid">16248211</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
